BEO Therapeutics

Dedicated to develop oral microbiome therapies that counteract diseases caused by metabolic waste products as gouty arthritis and (cardio-) metabolic diseases

Problem

Hyperuricemic patients have an altered gut microbiome that promotes disease.
The recommended diet is demanding and it is the only effective non-prescription treatment.
Current prescription medicines are effective in only 30-50% of patients.

Need

A treatment for hyperuricemic patients that pre-empts disease.
A treatment for the 50% of patients not responding to current therapies.

Solution

Oral microbiome treatments for chronic administration.
Re-balanced gut microbiome and urate metabolism.
Treatment that compliments strict diet and drugs

Our unfair advantage



… combining pharmaceutical and nutritional knowledge to the ‘sweet-spot´ between food and pharma…

Beo Therapeutics works selectively with a small fraction of human gut bacteria that are considered safe for human consumption. The bacteria carry the designation Qualified Presumption of Safety (QPS).

Focusing on QPS bacteria has several benefits:

  • QPS approved bacteria can be fast-tracked into human clinical studies under food-supplement regulation (non-IND study). This approach reduces cost and timelines to clinical PoC.
  • QPS products can be commercialised as food-supplements, medical foods or as (non-) prescription drugs. The multiple options reduce product development risk.